iRadimed Corporation (IRMD) is a publicly traded Healthcare sector company. As of October 30, 2026, IRMD trades at $79.20 with a market cap of $1.07B and a P/E ratio of 48.22. IRMD moved -7.21% today. Year to date, IRMD is -12.78%; over the trailing twelve months it is +9.49%. Its 52-week range spans $47.48 to $107.90. Analyst consensus is buy with an average price target of $120.00. Rallies surfaces IRMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IRadimed Q3 revenue beats estimates as 3870 pump launch drives record bookings: IRadimed reported third-quarter revenue of $24.20 million, up 14% year over year and above the $23.47 million consensus estimate. It narrowed 2026 guidance to revenue of $91.6 million-$93.1 million and GAAP diluted EPS of $1.90-$1.94, and expects fourth-quarter revenue of $25.0 million-$26.5 million.
| Metric | Value |
|---|---|
| Price | $79.20 |
| Market Cap | $1.07B |
| P/E Ratio | 48.22 |
| EPS | $1.81 |
| Dividend Yield | 0.20% |
| 52-Week High | $107.90 |
| 52-Week Low | $47.48 |
| Volume | 51.25K |
| Avg Volume | 0 |
| Revenue (TTM) | $86.34M |
| Net Income | $23.05M |
| Gross Margin | 75.86% |
2 analysts cover IRMD: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $120.00.